rs10848554 — ADIPOR2

ADIPOR2 rs10848554: A Haplotype Tag for Reduced Hepatic Adiponectin Signaling

Adiponectin is one of the most abundant hormones secreted by fat tissue, with a critical and counterintuitive property: its levels fall as body fat increases, precisely when the body needs its metabolic protection most. Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease¹¹ Low circulating adiponectin is a consistent predictor of insulin resistance, type 2 diabetes, dyslipidaemia, and cardiovascular disease
Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. Adiponectin acts exclusively through two transmembrane receptors: ADIPOR1, which dominates in skeletal muscle, and ADIPOR2, which dominates in the liver. rs10848554 is an intronic variant in the ADIPOR2 gene — it does not change the receptor's amino acid sequence, but it co-segregates with other ADIPOR2 variants that alter receptor expression and cardiovascular risk, tagging a shared haplotype across this locus.

The Mechanism

When adiponectin binds ADIPOR2 in hepatocytes, two downstream signaling arms activate: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master energy sensor that shifts the liver from fat synthesis to fat oxidation, suppresses gluconeogenesis, and improves glucose uptake and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that drives transcription of hepatic fatty acid oxidation genes; ADIPOR2 is its primary activator in liver. Together these pathways reduce hepatic triglyceride accumulation, improve LDL clearance, lower fasting glucose, and suppress inflammatory lipid species. When ADIPOR2 expression is reduced — as happens in visceral obesity — PPARα and AMPK signaling in the liver falls, creating rising triglycerides, impaired LDL clearance, and growing insulin resistance⁴⁴ When ADIPOR2 expression is reduced — as happens in visceral obesity — PPARα and AMPK signaling in the liver falls, creating rising triglycerides, impaired LDL clearance, and growing insulin resistance
Demonstrated in both human liver biopsies from obese subjects and mouse models of visceral adiposity. The C allele at rs10848554 tags a haplotype at the ADIPOR2 locus associated with this impaired signaling state.

The Evidence

The primary evidence for rs10848554 comes from the Finnish Diabetes Prevention Study (DPS)⁵⁵ Finnish Diabetes Prevention Study (DPS)
A landmark randomized lifestyle intervention trial enrolling individuals with impaired glucose tolerance; the DPS genotyping sub-study examined 484 participants for ADIPOR2 variants and followed them for a median of 10.2 years for cardiovascular events and diabetes progression. Eight ADIPOR2 SNPs were analyzed; rs10848554 was one of four that showed initial association with cardiovascular disease risk, alongside rs11061937, rs1058322, and rs16928751. These four variants were entered into a joint multi-SNP model, in which rs11061937 (p = 0.014) and rs1058322 (p = 0.020) retained independent significance. rs10848554 and rs16928751 did not maintain independent significance after adjusting for the other two variants — indicating that rs10848554 tags overlapping genetic information captured by the stronger signals, consistent with its role as part of an extended ADIPOR2 haplotype.

The broader biological context is well-supported. Synthetic AdipoR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance, improve glucose tolerance, and extend lifespan in obese diabetic mice⁶⁶ Synthetic AdipoR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance, improve glucose tolerance, and extend lifespan in obese diabetic mice
Okada-Iwabu et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, validating the receptor pathway as causally relevant to metabolic and cardiovascular outcomes. Hepatic ADIPOR2 is specifically downregulated in visceral obesity while ADIPOR1 expression is preserved⁷⁷ while ADIPOR1 expression is preserved
Bjursell M et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes, 2007, making it a vulnerable node where genetic and environmental risk factors converge.

Practical Actions

The actionable strategy for ADIPOR2 haplotype variants is to raise circulating adiponectin concentration — increasing ligand availability to compensate for any receptor-level impairment — while independently supporting the AMPK and PPARα pathways through dietary fat composition. Omega-3 fatty acids (EPA and DHA) consistently raise serum adiponectin in intervention studies and support hepatic fatty acid oxidation. Replacing saturated fat with polyunsaturated fat raises adiponectin by 10–15% in controlled dietary trials. Given the Finnish DPS finding linking this variant cluster to cardiovascular outcomes in at-risk individuals, fasting cardiometabolic monitoring is appropriate for C allele carriers, particularly those with impaired fasting glucose, elevated triglycerides, or a family history of cardiovascular disease.

Interactions

rs10848554 was genotyped alongside rs11061937, rs1058322, and rs16928751 in the Finnish DPS, all four showing nominal CVD association. Because rs10848554's association did not survive multi-variant adjustment, it most likely tags the same functional haplotype as the two independently significant variants — rs11061937 and rs1058322 — rather than an independent signal. Individuals carrying C alleles at multiple ADIPOR2 loci (rs10848554, rs11061937, rs1058322) likely carry the full ADIPOR2 risk haplotype, with compounded reduction in hepatic adiponectin responsiveness. For individuals who also carry lipid metabolism risk variants (e.g., in APOE, LDLR, or FADS genes), the combination of impaired ADIPOR2 signaling with intrinsically dysregulated lipid handling may represent a more substantial cardiometabolic risk profile than either pathway alone.